104 related articles for article (PubMed ID: 17380212)
1. Mecasermin rinfabate.
Kemp SF
Drugs Today (Barc); 2007 Mar; 43(3):149-55. PubMed ID: 17380212
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
Kemp SF
BioDrugs; 2009; 23(3):155-63. PubMed ID: 19627167
[TBL] [Abstract][Full Text] [Related]
3. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of mecasermin rinfabate.
Kemp SF; Fowlkes JL; Thrailkill KM
Expert Opin Biol Ther; 2006 May; 6(5):533-8. PubMed ID: 16610982
[TBL] [Abstract][Full Text] [Related]
5. Investigational agents for the treatment of growth hormone-insensitivity syndrome.
Kemp SF; Thrailkill KM
Expert Opin Investig Drugs; 2006 Apr; 15(4):409-15. PubMed ID: 16548790
[TBL] [Abstract][Full Text] [Related]
6. Mecasermin.
Keating GM
BioDrugs; 2008; 22(3):177-88. PubMed ID: 18481900
[TBL] [Abstract][Full Text] [Related]
7. Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.
Williams RM; McDonald A; O'Savage M; Dunger DB
Expert Opin Drug Metab Toxicol; 2008 Mar; 4(3):311-24. PubMed ID: 18363546
[TBL] [Abstract][Full Text] [Related]
8. Mecasermin Tercica.
Norman P
Curr Opin Investig Drugs; 2006 Apr; 7(4):371-80. PubMed ID: 16625824
[TBL] [Abstract][Full Text] [Related]
9. SomatoKine: is there a use in treating growth disorders?
Kemp SF; Thrailkill KM
Curr Opin Investig Drugs; 2005 Apr; 6(4):373-7. PubMed ID: 15898344
[TBL] [Abstract][Full Text] [Related]
10. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
Tonella P; Flück CE; Mullis PE
Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
[TBL] [Abstract][Full Text] [Related]
13. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
Clemmons DR; Sleevi M; Allan G; Sommer A
J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
[TBL] [Abstract][Full Text] [Related]
14. Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans.
Lieberman SA; Bukar J; Chen SA; Celniker AC; Compton PG; Cook J; Albu J; Perlman AJ; Hoffman AR
J Clin Endocrinol Metab; 1992 Jul; 75(1):30-6. PubMed ID: 1377706
[TBL] [Abstract][Full Text] [Related]
15. Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats.
Fielder PJ; Mortensen DL; Mallet P; Carlsson B; Baxter RC; Clark RG
Endocrinology; 1996 May; 137(5):1913-20. PubMed ID: 8612531
[TBL] [Abstract][Full Text] [Related]
16. Mecasermin: new drug. Insufficient improvement in statural growth.
Prescrire Int; 2009 Jun; 18(101):111-3. PubMed ID: 19637420
[TBL] [Abstract][Full Text] [Related]
17. Mecasermin (recombinant human insulin-like growth factor I).
Rosenbloom AL
Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
[TBL] [Abstract][Full Text] [Related]
18. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
[TBL] [Abstract][Full Text] [Related]
19. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-I increases astrocyte intercellular gap junctional communication and connexin43 expression in vitro.
Aberg ND; Blomstrand F; Aberg MA; Björklund U; Carlsson B; Carlsson-Skwirut C; Bang P; Rönnbäck L; Eriksson PS
J Neurosci Res; 2003 Oct; 74(1):12-22. PubMed ID: 13130502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
